Q1 EPS Estimate for Stoke Therapeutics Reduced by Analyst

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Wedbush lowered their Q1 2025 EPS estimates for shares of Stoke Therapeutics in a report issued on Wednesday, February 19th. Wedbush analyst L. Chico now expects that the company will post earnings of ($0.58) per share for the quarter, down from their prior estimate of ($0.56). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.55) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2025 earnings at ($2.40) EPS, FY2026 earnings at ($3.06) EPS, FY2027 earnings at ($3.16) EPS, FY2028 earnings at ($2.71) EPS and FY2029 earnings at ($2.03) EPS.

A number of other equities research analysts have also commented on STOK. Cantor Fitzgerald reiterated an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Chardan Capital reiterated a “buy” rating and set a $24.00 price target on shares of Stoke Therapeutics in a report on Wednesday. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday, February 18th. Finally, HC Wainwright upped their price target on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Stock Performance

Shares of STOK opened at $8.33 on Friday. The firm has a market cap of $441.24 million, a price-to-earnings ratio of -3.97 and a beta of 0.95. Stoke Therapeutics has a fifty-two week low of $5.21 and a fifty-two week high of $17.58. The firm has a 50 day moving average price of $10.55 and a 200-day moving average price of $12.27.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 13,666 shares of the company’s stock in a transaction dated Monday, December 9th. The shares were sold at an average price of $13.61, for a total transaction of $185,994.26. Following the transaction, the general counsel now owns 21,476 shares in the company, valued at approximately $292,288.36. This represents a 38.89 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Barry Ticho sold 10,000 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $12.07, for a total transaction of $120,700.00. Following the transaction, the insider now owns 51,277 shares in the company, valued at $618,913.39. This represents a 16.32 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,849 shares of company stock worth $809,421. Company insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Several institutional investors have recently made changes to their positions in STOK. Mesirow Financial Investment Management Inc. bought a new position in shares of Stoke Therapeutics in the 3rd quarter worth approximately $192,000. Los Angeles Capital Management LLC lifted its stake in shares of Stoke Therapeutics by 54.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 103,005 shares of the company’s stock worth $1,266,000 after purchasing an additional 36,240 shares during the period. Intech Investment Management LLC bought a new position in shares of Stoke Therapeutics in the 3rd quarter worth approximately $160,000. Charles Schwab Investment Management Inc. lifted its stake in shares of Stoke Therapeutics by 9.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 316,134 shares of the company’s stock worth $3,885,000 after purchasing an additional 26,870 shares during the period. Finally, BNP Paribas Financial Markets raised its stake in Stoke Therapeutics by 1,589.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after acquiring an additional 71,647 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.